ClinicalTrials.gg
CompletedNCT01870297Updated Jan 24, 2019Results posted

A Study of LY3025876 in Participants With Diabetes

A Phase 1 interventional study of LY3025876 and Placebo in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-01-24.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
68th of 151
72 · median 62
Started
2013
with 17 others
Phase 1
25 of 151
none open now
Registered
78th of 151
by date
Lead sponsor
2 of 151
Eli Lilly and Company

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 68th largest by enrollment, is one of 18 that started in 2013, is one of 25 in phase 1, and was the 78th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).

Read the detailed description

This study will also evaluate how much of the study drug enters the blood stream and how long it takes for the body to remove the study drug. Information about any side effects that may occur will also be collected. Participants will continue their usual diet and exercise program and may remain on their physician-prescribed dose of metformin.

Each part of the study is expected to last 10 to 12 weeks on average, not including screening. Participants may only enroll in one part.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus (T2DM) as determined by the investigator, controlled with diet or exercise alone or on a stable dose of metformin for at least 30 days
  • Have a (BMI) greater than or equal to 23 and less than or equal to 45 kilograms per square meter (kg/m\^2) at screening
  • Have a supine blood pressure reading at screening of between 90-160 millimeter of mercury (mmHg) (systolic) and 40-95 mmHg (diastolic)
  • Women not of due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause

Exclusion criteria

Exclusion Criteria:

  • Have taken LY3025876 or drugs like it (for example, other fibroblast growth factor-21 [FGF21]-related drugs) or have known allergies to these drugs
  • History or presence of bone disease (including osteoporosis or unhealed fractures)
  • Current active treatment of periodontal disease
  • Have had a significant change in weight, defined as a gain or loss of at least 4 kilogram (kg) (9 pounds) in the last 3 months
  • Have had greater than 1 episode of severe hypoglycemia within 6 months of screening that required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions or had a seizure or coma
  • Have known allergies or a history of intolerance to liraglutide, glucagon-like peptide 1 (GLP-1) analogues, or other related compounds
  • Have a history of acute or chronic pancreatitis
  • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    LY3025876

    Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days.

    Drug: LY3025876

  • Placebo comparator
    Placebo

    Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days

    Drug: Placebo

  • Experimental
    LY3025876 + Liraglutide

    Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.

    Drug: LY3025876 · Drug: Liraglutide

  • Placebo comparator
    Placebo + Liraglutide

    Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.

    Drug: Placebo · Drug: Liraglutide

Interventions

  • DrugLY3025876

    Administered SQ

  • DrugPlacebo

    Administered SQ

  • Administered SQ

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.

    Time frame: Predose on Day 1 up to Day 56 in each Part

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC[0-24]) of LY3025876

    AUC(0-24) of individual participants was calculated by equation Area Under Concentration (AUC)=Dose/CL, where the clearance (CL) was estimated using a population PK model.

    Time frame: Predose and 0.5 hour(hr), 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 12 hr, and 24 hr Postdose

  2. PK: Maximum Concentration (Cmax) of LY3025876

    Time frame: Days 1 and 28: Predose and 0.5 hr, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 12 hr, and 24 hr Postdose

  3. Part A and Part B: Immunogenicity: The Number of Participants With Anti-LY3025876 Antibodies

    Time frame: Predose on Day 7, 14, 28, 56, and 180

  4. Pharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose

    Least Squares Mean (LS) Mean change from baseline in fasting glucose was modeled using Mixed Effect Model Repeat Measurement (MMRM) analysis with fixed effects of baseline, treatment, day, treatment\*day interaction, and participant as a random effect.

    Time frame: Baseline, Day 28

07

Results

Posted Jan 24, 2019

Participant flow

Participant flow — Overall Study
MilestonePlacebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + Lirgalutide
Started11158910910
Completed11879788
Not completed0710312
Withdrew: Adverse event0000200
Withdrew: Lost to follow-up0110000
Withdrew: Withdrawal by subject0000111
Withdrew: Sponsor decision0600001

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.

Time frame:
Predose on Day 1 up to Day 56 in each Part
Reported as:
Number · participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
participantsPlacebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + Liraglutide
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration0000000
SecondaryPharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC[0-24]) of LY3025876

AUC(0-24) of individual participants was calculated by equation Area Under Concentration (AUC)=Dose/CL, where the clearance (CL) was estimated using a population PK model.

Time frame:
Predose and 0.5 hour(hr), 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 12 hr, and 24 hr Postdose
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC[0-24]) of LY3025876
nanograms*hour/milliliter (ng*hr/mL)0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876LY3025876 + Liraglutide
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC[0-24]) of LY302587651.5 ± 61.1207 ± 51.2622 ± 42.31930 ± 32.4525 ± 37.8
SecondaryPK: Maximum Concentration (Cmax) of LY3025876
Time frame:
Days 1 and 28: Predose and 0.5 hr, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 12 hr, and 24 hr Postdose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of LY3025876
nanogram/milliliter (ng/mL)0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY30258765.0 mg LY3025876 + Liraglutide
Day 13.90 ± 33.717.5 ± 43.745.1 ± 39.2126 ± 44.340.3 ± 48.3
Day 284.87 ± 85.714.2 ± 46.151.9 ± 31.3185 ± 26.844.8 ± 53.8
SecondaryPart A and Part B: Immunogenicity: The Number of Participants With Anti-LY3025876 Antibodies
Time frame:
Predose on Day 7, 14, 28, 56, and 180
Reported as:
Count of participants · Participants
Part A and Part B: Immunogenicity: The Number of Participants With Anti-LY3025876 Antibodies
ParticipantsPlacebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + Liraglutide
Positive Antibodies Day 70000101
Positive Antibodies Day 140100001
Positive Antibodies Day 280122601
Positive Antibodies Day 560142601
Positive Antibodies Day 1800001400
SecondaryPharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose

Least Squares Mean (LS) Mean change from baseline in fasting glucose was modeled using Mixed Effect Model Repeat Measurement (MMRM) analysis with fixed effects of baseline, treatment, day, treatment\*day interaction, and participant as a random effect.

Time frame:
Baseline, Day 28
Reported as:
Least squares mean · milligram/deciliter (mg/dL)
Pharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose
milligram/deciliter (mg/dL)Placebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo Part B5.0 mg LY3025876 + Liraglutide
Pharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose3.52 ± 8.4118.08 ± 10.020.12 ± 9.92-14.50 ± 9.3322.96 ± 11.5111.72 ± 5.946.32 ± 5.64

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Part A—0/11 (0%)5/11 (45.5%)
0.5 mg LY3025876—0/15 (0%)7/15 (46.7%)
1.5 mg LY3025876—0/8 (0%)8/8 (100%)
5.0 mg LY3025876—0/9 (0%)9/9 (100%)
15 mg LY3025876—0/10 (0%)10/10 (100%)
Placebo Part B—0/9 (0%)9/9 (100%)
Placebo + Liraglutide—0/10 (0%)9/10 (90%)
Most frequent other events
Showing 10 of 67
Most frequent other events
EventPlacebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo Part BPlacebo + Liraglutide
DiarrhoeaGastrointestinal disorders0/111/151/81/99/100/93/10
Frequent bowel movementsGastrointestinal disorders1/110/152/86/90/100/91/10
Decreased appetiteMetabolism and nutrition disorders0/111/151/80/90/104/95/10
NauseaGastrointestinal disorders0/110/151/82/93/104/94/10
Injection site haemorrhageGeneral disorders1/110/150/80/90/104/91/10
Early satietyGeneral disorders0/110/150/80/91/102/94/10
Injection site erythemaGeneral disorders0/110/150/80/94/102/92/10
Injection site pruritusGeneral disorders0/111/152/80/94/101/91/10
Injection site rashGeneral disorders0/110/150/80/91/100/94/10
Dermatitis contactSkin and subcutaneous tissue disorders0/110/153/80/90/100/91/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + LiraglutideTotal
Age Part A53.4 ± 9.655.8 ± 7.653.3 ± 7.261.9 ± 5.555.3 ± 6.8NA ± NANA ± NA55.8 ± 7.8
Age Part BNA ± NANA ± NANA ± NANA ± NANA ± NA53.2 ± 8.954.4 ± 5.553.8 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + LiraglutideTotal
Female454222322
Male7104787750
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + LiraglutideTotal
Hispanic or Latino10137666351
Not Hispanic or Latino121343721
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + LiraglutideTotal
American Indian or Alaska Native00000000
Asian00010012
Native Hawaiian or Other Pacific Islander00000000
Black or African American02010148
White111387108562
More than one race00000000
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(participants)Placebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + LiraglutideTotal
United States1115891091072
Glycosylated Hemoglobin (HbA1c)
Glycosylated Hemoglobin (HbA1c)(percent of HbA1c)Placebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + LiraglutideTotal
HbA1c Part A8.64 ± 0.658.39 ± 0.938.43 ± 0.888.94 ± 1.198.67 ± 0.92NA ± NANA ± NA8.59 ± 0.91
HbA1c Part BNA ± NANA ± NANA ± NANA ± NANA ± NA8.56 ± 0.778.05 ± 0.868.29 ± 0.84
Fasting Serum Glucose (FSG)
Fasting Serum Glucose (FSG)(milligram/deciliter (mg/dL))Placebo Part A0.5 mg LY30258761.5 mg LY30258765.0 mg LY302587615 mg LY3025876Placebo + Liraglutide5.0 mg LY3025876 + LiraglutideTotal
FSG Part A164.43 ± 31.59148.08 ± 19.14181.27 ± 47.84175.74 ± 75.99145.66 ± 23.22NA ± NANA ± NA161.63 ± 42.87
FSG Part BNA ± NANA ± NANA ± NANA ± NANA ± NA159.73 ± 36.54152.22 ± 26.62155.78 ± 31.02
08

Study locations

4 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chula Vista, California 91911, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orange, California 92868, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33143, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cincinnati, Ohio 45227, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2013
First posted
Jun 6, 2013
Start
Jun 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Jan 24, 2019
Last update
Jan 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01870297
Responsible party
Sponsor
First posted
Jun 6, 2013
Start date
Jun 2013
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Jan 24, 2019
Last update
Jan 24, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion